SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is trending as investors eagerly await a "game-changer" partnership announcement, hinted at by management as coming prior to the new year. This potential alliance, especially in the federal and sovereign AI sectors, is fueling strong bullish sentiment for a significant revenue boost and short squeeze, though some in the community express skepticism over its timing and market impact.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

Mannatech (MTEX) is currently trending due to its exceptionally low public float, which is generating significant retail investor interest and speculation for a potential short squeeze. The community is actively discussing the stock's potential for rapid upward movement, with many eyeing key resistance levels and recent strong profitability metrics as drivers, despite some acknowledgment of past revenue trends. This micro-cap's tight share structure and increasing volume are fueling intense conversation around its parabolic breakout potential.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is trending due to a proposed merger with Applied Digital's cloud computing business, aiming to pivot into an AI GPU compute platform named ChronoScale. This potential transformation from a medical device company to an AI infrastructure player is driving market conversation. The community is actively discussing the implications of this shift, with many anticipating a significant re-rating given exposure to AI and a low share float, though some express concerns regarding shareholder dilution.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is trending with significant pipeline news, including positive Phase 2 results for its obesity drug MariTide, which showed strong weight loss but also prompted community discussion around tolerability and potential dosing adjustments. Further boosting its portfolio, the company recently reported successful Phase 3 data for its Repatha cholesterol drug, alongside new FDA approvals for therapies in generalized myasthenia gravis and lung cancer, all while strategically engaging on U.S. drug pricing.

Roundhill ETF Trust - Roundhill GLP-1 & Weight Loss ETF

Roundhill GLP-1 & Weight Loss ETF

The Roundhill GLP-1 & Weight Loss ETF ($OZEM) is drawing significant attention as the therapeutic scope for GLP-1 drugs rapidly expands beyond obesity, with recent regulatory milestones for new indications fueling optimism. Investors are actively discussing the potential for increased insurance coverage and the long-term growth trajectory of this innovative sector, despite ongoing competitive dynamics.

Intelligent Living Application Group, Inc. engages in the manufacturing and selling of mechanical locksets. It focuses in producing mechanical locksets including locksets for outdoors such as main entrances and gates and indoors. The firm offers a range of original design manufacturer door locksets to various customer segments with classic to contemporary looks, functions and colors. The company was founded by Po Wang Hui in 1981 and is headquartered in Hong Kong.

Intelligent Living Application Group Inc

Intelligent Living Application Group is trending following strong revenue and gross profit growth reported in its latest financials, along with recent product launches in the smart lock market. Community discussion emphasizes the stock's potential for a significant upward move, drawing comparisons to other volatile Chinese and Hong Kong micro-cap names known for explosive price action and speculating on a potential short squeeze and active accumulation.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending due to compelling preliminary Phase 3 data showing a significant reduction in breast cancer recurrence rates and a strategic extension of insider share lock-ups through September 2026. The community is actively discussing a potential short squeeze, fueled by the stock's low float, extremely high cost-to-borrow rates, and substantial trading volume, with many anticipating significant long-term gains and potential acquisition interest for its promising GLSI-100 immunotherapy.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as its innovative pipeline continues to impress, with positive trial data for its next-generation obesity drug, retatrutide, and high anticipation for its oral GLP-1, orforglipron. The community is actively debating LLY's market leadership against fierce competition in the rapidly expanding weight-loss sector, with strong bullish sentiment contrasted by concerns over valuation and the competitive landscape. This ongoing innovation and strategic manufacturing expansion are cementing its role as a pharmaceutical giant.

Global X Funds - Global X Uranium ETF

Global X Uranium ETF

The Global X Uranium ETF is trending as the community increasingly links burgeoning AI energy demand to a critical need for stable nuclear power, solidifying uranium's strategic resource status. Investors are actively discussing the recent inclusion of uranium on the U.S. critical minerals list and a persistent supply deficit, further amplified by continuous buying from investment vehicles and supportive government policies. This confluence of factors underpins a strong long-term bullish outlook for the sector.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileye Global is at the center of a divided community discussion following recent earnings, which, despite meeting expectations, did little to stem the stock's ongoing decline. Investors are actively debating the long-term potential of its autonomous driving technology and partnerships, such as with lidar provider Innoviz, against a backdrop of market skepticism and intense competition. While many lament the stock's performance, a counter-narrative sees the current levels as an opportune entry point given the company's strong fundamentals and future prospects in ADAS and robotaxis.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
